ライフサイエンスコーパス: type V

1 cies (type IV), and Propionibacterium acnes (type V).

2 elic disorder distal spinal muscular atrophy type V.

3 '-UTR of BRIL causes osteogenesis imperfecta type V.

4 that is involved in osteogenesis imperfecta type V.

5 uch more hyperpolarized potentials than wild type (V(1/2) of s(infinity) curve approximately -130 mV

6 referential reliance on [1 - C] (mostly A, B types) vs (3) preferential reliance on [1 - Q] (mostly C

7 e I: 6, Type 2: 6, Type III: 6, Type IV: 11, Type V: 4.

8 Hereditary Sensory and Autonomic Neuropathy type V, a rare disease characterized by impaired nocicep

9 s counteract Cas12a with inhibitors, notably type V-A anti-CRISPRs (AcrVAs).

10 an RNA-guided endonuclease in the bacterial type V-A CRISPR-Cas anti-phage immune system that can be

11 ers were significantly more elevated in wild-type vs. Aag(-/-) liver after I/R.

12 mmunostaining with anticollagen type III and type V Abs).

13 main and C2 regions from type I AC (ACI) and type V AC (ACV) to identify the region on ACI that inter

14 new studies report that recently discovered type V Acr proteins use enzymatic activities to shut dow

15 ism whereby Ca(2+) inhibits adenylyl cyclase type V (ACV) and adenylyl cyclase type VI (ACVI) is unkn

16 second of the two large cytosolic domains of type V adenylyl cyclase (ACV) as bait, we identified a s

17 at besides catalyzing the synthesis of cAMP, type V adenylyl cyclase (ACV) can act as a GTPase-activa

18 th Myc (PAM) interacts with the C2 domain of type V adenylyl cyclase (ACV-C2) and that purified PAM i

19 ibrary, using the N-terminal region of human type V adenylyl cyclase (hACV) as bait, we identified G

20 tly with the C(1) but not the C(2) domain of type V adenylyl cyclase and that the inhibition by RGS2

21 and apparent affinity for the C(1) domain of type V adenylyl cyclase in the absence of activators of

22 Type V adenylyl cyclase was decreased approximately 45%

23 In HEK293 cells expressing type V adenylyl cyclase, RGS2 inhibited Galpha(s)-Q227L-

24 e nature of the interaction between RGS2 and type V adenylyl cyclase.

25 Comparisons of cells from wild-type vs. AE3(-/-) mice show that AE3 (present in hippoca

26 of the extracellular matrix protein collagen type V alpha 1 (col5a1).

27 ic cells) include aminopeptidase A, collagen type V, alpha 1, cyclin G2, DEC1/Stra13, endothelin 1, l

28 This polypeptide, which we have named alpha4 type V (alpha4(V)) collagen, contains an uninterrupted G

29 xpand on these observations to show that GBS type V, an emergent serotype, grown in a chemostat at a

30 taining (400 endotoxin units/ml) collagenase type V and "endotoxin-free" (3.1 endotoxin units/ml) Lib

31 nt manner and also appeared to bind collagen type V and laminin, but not other proteins, such as tran

32 maS and the catalytic C1 and C2 domains from type V and type II mAC (VC1.IIC2), bound to FSK and eith

33 Galpha(s) and Galpha(i) regulation of human type V and type VI adenylyl cyclase (AC V and AC VI) in

34 Type V and VI mammalian adenylyl cyclases (AC5, AC6) are

35 fication of BKV into six genotypes, of which types V and VI have not been previously recognized.

36 ithelium-derived factor (PEDF) defects cause types V and VI osteogenesis imperfecta via defective bon

37 d 29 had darker skin types (Fitzpatrick skin types V and VI).

38 (skin types I, II, III, and IV) than in skin types V and VI-which are reported to tolerate relatively

39 at efficiently cleaves gelatin, elastin, and types V and X collagen.

40 MODY5 (maturity-onset diabetes of the young, type V) and familial GCKD (glomerulocystic kidney diseas

41 Adenylyl cyclase (Type V) and its subdomains, which interact with Gsalpha,

42 meability in isolated choroid plexus of wild-type vs. AQP1 null mice, as well as intracranial pressur

43 y times of 17 +/- 0.7 vs. 55 +/- 5 s in wild-type vs. AQP4-null mice in a buried food pellet test, wh

44 ctions caused by group B streptococcal (GBS) type V are increasingly common.

45 l of endogenous nucleotide bound to the wild-type V-ATPase and to a mutant (the A subunit mutant R483

46 This protease is a founding member of the type V (autotransporter) secretion system and is conside

47 stems, one putative Type IV system and three Type V autotransporters.

48 2c1 is a newly identified guide RNA-mediated type V-B CRISPR-Cas endonuclease that site-specifically

49 hat are secreted via the autotransporter (or type V) bacterial secretion pathway.

50 Type I and type V behaviors of the International Union of Pure and

51 for heterogeneity = .037, between BRAF-wild-type vs BRAF-mutated cancer risks).

52 ngs to the widely conserved, uncharacterized type V branch of P-type ATPases, a large family of ion p

53 of amylose-lipid complexes (Resistant Starch Type V) by the addition of different lipids/fatty acids

54 Most type V-C and V-D systems lack the cas2 gene and have unu

55 we show that a mini-integrase comprising the type V-C Cas1 protein alone catalyzes DNA integration wi

56 ted by conjugates prepared with purified GBS type V capsular polysaccharide (CPS) than among those ev

57 ted with a greater percentage of Type IV and Type V cases.

58 robability of release (0.27 vs 0.46 for wild-type vs CaSR(-/-) pairs) with little change in quantal s

59 The fact that several GBS type V cell wall-associated and membrane proteins were e

60 udes a myosin motor-like sequence fused to a type V chitin synthase gene.

61 ifferential RNA sequencing (RNA-seq) of wild-type V. cholerae and a locked low-cell-density QS-mutant

62 only those amino acids was secreted by wild-type V. cholerae but not by an epsD mutant, establishing

63 During microcolony formation, wild-type V. cholerae cells tended to exist as straight rods,

64 In this work, we have isolated the wild-type V. cholerae monolayer and demonstrated that the env

65 ingested approximately 1 x 10(5) CFU of wild-type V. cholerae O1 El Tor Inaba strain N16961 10 days o

66 ed with 10(6) CFU (one 50% lethal dose) wild-type V. cholerae O1 El Tor strain N16961.

67 Wild-type V. cholerae strains 3038 and C7258 and a vaccine ca

68 , significantly increased attachment of wild-type V. cholerae to Caco-2 cells.

69 By comparing TcpP diffusion in wild-type V. cholerae to that in mutant strains lacking eithe

70 n for the V. cholerae T2S system, since wild-type V. cholerae was found to secrete the biofilm matrix

71 Like E. coli, but unlike wild-type V. cholerae, motility of some V. cholerae strains c

72 Unlike wild-type V. cholerae, mutants lacking wigR fail to recover f

73 indistinguishable from those formed by wild-type V. cholerae.

74 requirements for monolayer formation by wild-type V. cholerae.

75 ty was not detected in cell extracts of wild-type V. cholerae.

76 The CRISPR-Cas12a is a class II, type V clustered regularly interspaced short palindromic

77 allograft rejection is mediated by collagen type V (col(V)) specific T-helper-cell 17 (Th17) cells.

78 We recently identified the collagen type V [col(V)] alpha1(V) chain as a key autoantigen dri

79 e role of cell-mediated immunity to collagen type V [col(V)] in this process.

80 Autoimmunity to type V collagen (col(V)) is a major risk factor for lung

81 We reported that anti-type V collagen (col(V)) T cell immunity was strongly as

82 ne response to a native protein in the lung, type V collagen (col(V)), and that col(V)-induced oral t

83 Immunity to type V collagen [col(V)] contributes to lung transplant

84 Aberrant expression of the type V collagen alpha1(V) chain can underlie the connect

85 Type V collagen also exists as an alpha1(V)alpha2(V)alph

86 ion involves IL-17-regulated autoimmunity to type V collagen and alloimmunity, which could be enhance

87 ) specifically enhance its ability to cleave type V collagen and gelatin, respectively.

88 Transforming growth factor-beta and type V collagen are targets for regulating the initial f

89 trimers, thus completing characterization of type V collagen biosynthetic processing.

90 Digestion of type V collagen by the gelatinases is an important step

91 date the mechanism whereby half-reduction of type V collagen causes abnormal connective tissue biogen

92 The reduced type V collagen content is associated with a 50% reducti

93 The type V collagen domain but not the alpha4(V) N-terminal

94 the new 75-kDa chicken gelatinase lacks the type V collagen domain that is found in all mammalian ge

95 and spreading on dishes coated with various type V collagen domains revealed that Schwann cells adhe

96 Previously, we identified a type V collagen family member, alpha4(V) collagen, which

97 Type V collagen has been implicated in the regulation of

98 gene that encodes the proalpha1(V) chain of type V collagen in the classical form of the Ehlers-Danl

99 ose of this study was to define the roles of type V collagen in the regulation of collagen fibrilloge

100 a central role for the evolutionary, ancient type V collagen in the regulation of fibrillogenesis.

101 Type V collagen incorporates into type I collagen fibril

102 Type V collagen is a quantitatively minor fibrillar coll

103 data, we identified and then confirmed that type V collagen is an MMP-20 substrate.

104 e complete dependence of fibril formation on type V collagen is indicative of the critical role of th

105 Since type V collagen is not present in dental enamel but is a

106 reported recently preliminary evidence that type V collagen is required for collagen fibril nucleati

107 d the data are consistent with a mutation in Type V collagen leading to haploinsufficiency with the f

108 e found to be critical for interactions with type V collagen model substrates and inhibitors and to p

109 a1(V) mRNA relative to the levels of another type V collagen mRNA, proalpha2(V), were also observed i

110 a highly basic region (not present in other type V collagen NTD) as the site responsible for high af

111 erential modification of alpha1(V) chain and type V collagen properties.

112 evidence that the alpha chain composition of type V collagen remains alpha1(V)(2)alpha2(V) even in th

113 broblasts secreted only 65% of the amount of type V collagen secreted by normal controls.

114 Previously we reported that type V collagen synthesized by Schwann cells inhibits th

115 Type V collagen transcripts of affected individuals were

116 aling by transforming growth factor-beta and type V collagen were required for collagen fibrillogenes

117 production from alloantigen- or autoantigen (type V collagen)-reactive lymphocytes.

118 pe IV collagen alpha1 and alpha2 chains, (2) type V collagen, (3) type VI collagen, and most recently

119 reviously, we reported the cloning of alpha4 type V collagen, a novel member of the collagen type V g

120 haploinsufficiency of proalpha1(V) chains of type V collagen, a quantitatively minor collagen that co

121 ppressed DTH responses to donor antigens and type V collagen, abrogated local production of tumor nec

122 e (THP) models of the MMP-9 cleavage site in type V collagen, alpha1(V)436-450 THP and alpha1(V)436-4

123 tivity (DTH) responses to donor antigens and type V collagen, an autoantigen involved in the rejectio

124 in the COL5A1 and COL5A2 genes, which encode type V collagen, have been identified in several individ

125 ucted and found to selectively inhibit MMP-9 type V collagen-based activities compared with interstit

126 The type V collagen-deficient mice demonstrate a virtual lac

127 seen in cases with structural alterations in type V collagen.

128 endow the enzyme with the ability to cleave type V collagen.

129 t with type I collagen, type II collagen, or type V collagen.

130 s against lung-restricted self-Ags, collagen type V (ColV), and k-alpha1 tubulin (KAT).

131 Incomplete-type (vs complete-type) IM at baseline presented higher

132 GBS type V conjugate vaccines are safe and immunogenic and w

133 sensitivity to gap junction blockers in wild-type vs. connexin36 knockout mice.

134 PR-Cas systems, including type II-C Cas9 and type V Cpf1 systems, and can facilitate precise gene edi

135 th type V CPS is for chemically desialylated type V CPS (dV CPS).

136 cited in humans by a conjugate prepared with type V CPS is for chemically desialylated type V CPS (dV

137 as a mechanism for enhancing the ability of type V CPS to induce IgM-to-IgG switching.

138 Levels of serum antibodies to type V CPS were measured by ELISA, and functional activi

139 CPS-tetanus toxoid (TT) vaccine (n=15), GBS type V CPS-cross-reactive material (CRM(197)) conjugate

140 V-TT-induced type V CPS-specific antibodies promoted the opsonophagoc

141 Type V CPS-specific gene was present in 66% of the isola

142 Four-fold or greater increases in type V CPS-specific IgG concentrations were noted in pos

143 V-TT CV elicited significant increases in type V CPS-specific immunoglobulin (Ig) G, IgM, and IgA

144 Significant increases in type V CPS-specific immunoglobulin G (IgG) were elicited

145 Type V CPS-specific immunoglobulin M was a dominant isot

146 ized to receive an intramuscular dose of GBS type V CPS-tetanus toxoid (TT) vaccine (n=15), GBS type

147 id not affect the structural conformation of type V CPS.

148 CRISPR-Cas12a (Cpf1), a type V CRISPR-associated nuclease, provides bacterial im

149 Cas12i is a recently identified type V CRISPR-Cas endonuclease that predominantly cleave

150 diversity emerging along different routes of type V CRISPR-Cas evolution and expands the CRISPR toolb

151 Type V CRISPR-Cas interference proteins use a single Ruv

152 Cpf1 is an RNA-guided endonuclease of a type V CRISPR-Cas system that has been recently harnesse

153 Type V CRISPR-Cas systems are distinguished by a single

154 chanism that are fundamental features of all type V CRISPR-Cas systems.

155 xhibits various degrees of resistance to the type V CRISPR-Cas12a system, producing orders of magnitu

156 Type V CRISPR-Cas12a systems provide an alternate nuclea

157 The type-V CRISPR effector Cas12b (formerly known as C2c1) h

158 Collagen type V, decorin, fibromodulin, and tenascin-X proteins w

159 reasing severity of periodontal disease, and Type V defined referrals for needs other than periodonta

160 (HSP) and distal hereditary motor neuropathy type V (dHMN-V).

161 g proteins (VCBPs) consist of immunoglobulin-type V domains and a chitin-binding domain (CBD).

162 D (CMT2D) and distal spinal muscular atrophy type V (dSMA-V) are axonal neuropathies characterized by

163 D (CMT2D) and distal spinal muscular atrophy type V (dSMA-V) are axonal peripheral neuropathies inher

164 ly defined as distal spinal muscular atrophy type V (dSMA-V) in three families, Charcot-Marie-Tooth d

165 ery of the trans-cleavage property of CRISPR type V effectors makes CRISPR a potential high-accuracy

166 haride types, leading us to hypothesize that type V emerged from a recombination event in a type IX b

167 Categorized as class 2 type V-F, they originate from the previously identified

168 th in a glycerol/tryptone-based medium, wild-type V. fischeri cells initially excrete acetate but, in

169 As predicted, in the presence of NO, wild-type V. fischeri grew more slowly on hemin than a hnoX d

170 ion levels relative to that achieved by wild-type V. fischeri.

171 and by injection in vivo of TWEAK into wild-type vs Fn14-deficient mice.

172 The type V (for variable) promyelocytic leukemia retinoic ac

173 sphorylated or unphosphorylated form of wild-type v-Fps, with binding of the second Mg(2+) ion unaffe

174 sphorylated or unphosphorylated form of wild-type v-Fps, with substrate binding unaffected.

175 system, it is not expressed in the ventral D-type (VD) GABAergic motorneurons, which are defective in

176 The safety and immunogenicity of type V GBS capsular polysaccharide (CPS)-tetanus toxoid

177 ies promoted the opsonophagocytic killing of type V GBS in vitro.

178 est the potential for prevention of invasive type V GBS infections in healthy elderly adults through

179 e V collagen, a novel member of the collagen type V gene family that is expressed by Schwann cells in

180 ifies p200 as a novel member of the collagen type V gene family.

181 ctionally oriented CP and Rep, assigned as a type V genome organization.

182 Hereditary Sensory and Autonomic Neuropathy type V (HSAN V), caused by the 661C>T transition in the

183 machandran et al. argued that ICC neurons of types V, I, and O, respectively, receive their predomina

184 to heart allografts from MHC-mismatched wild-type vs ICAM-1(-/-) donors were tested.

185 les promoted opsonophagocytic killing of GBS type V in vitro, whereas those from placebo recipients d

186 n receptor antagonists and phosphodiesterase type V inhibitor have been shown to be useful to treat t

187 organ development and function depend on the type V intermediate filament proteins, the lamins, which

188 Cardiorenal syndrome type V is consistent with the process of preeclampsia su

189 The low abundance fibrillar collagen type V is incorporated into and regulates the diameters

190 The low abundance fibrillar collagen type V is widely distributed in tissues as an alpha1(V)(

191 to the extracellular space (Type I, Type IV, Type V) is required for establishing the symbiosis with

192 A shift of type V isolates into profile 4 subgroups may be indicati

193 Two-thirds of the type V isolates within profile group 4 were classified i

194 es in profile group 4 were highly related to type V isolates, as demonstrated by PFGE profiles, we in

195 strated by PFGE profiles, we investigated 45 type V isolates.

196 ostructural with SIFSIX-14-Cu-i, exhibited a type V isotherm and no phase change.

197 sts of Tn7-like transposase subunits and the type V-K CRISPR effector (Cas12k).

198 The wild-type V/K(malate) pH-rate profile exhibits the requiremen

199 GANP promoter activity was higher in wild-type vs Lyn-deficient cells.

200 ts in an enzyme that retains 24% of the wild-type V(max) value with a modest 5-fold increase in the K

201 pE and demonstrate that it is secreted via a type V mechanism.

202 nterval, 12.6-883) compared with other clone type/V-MIC combinations.

203 mice expressing restricting MHC on all cell types vs mice that specifically lack restricting MHC on

204 properties of alpha4(V)-containing collagen type V molecules suggest a unique and important role for

205 velopment, Schwann cells synthesize collagen type V molecules that contain alpha4(V) chains.

206 ation factors were extended RAS status (wild-type vs mutant) and time since diagnosis of first metast

207 95% CI 0.40-0.65 for KRAS mutant [KRAS wild type vs mutant, pinteraction=0.74]; HR 0.50, 95% CI 0.40

208 CI 0.32-0.89 for PIK3CA mutant [PIK3CA wild-type vs mutant, pinteraction=0.85]) or circulating DNA c

209 etween fitting different datasets (e.g. wild type vs. mutant).

210 edian overall survival of patients with wild-type vs. mutated ATM in MCL.

211 Delivery of Aip3p also requires the type V myosin motor Myo2p and its regulatory light-chain

212 ify She3p as an adaptor protein that links a type V myosin motor to specific ribonucleoproteins.

213 cterize the interaction between Sro7 and the type V myosin Myo2 and show that this interaction is imp

214 late Golgi elements to the bud requires the type V myosin Myo2p, further suggesting that actin plays

215 is most important for ring constriction, and type V myosin Myo51 aids the other two myosins." Zambon

216 the type II myosins Myo2p and Myp2p and the type V myosin Myo51p [2].

217 nization during cytokinesis, distribution of type V myosin Myo52 to the division site, and timely rec

218 Here, we show that the type V myosin myoJ localizes to CV membranes and is requ

219 In addition, this process requires the type V myosin protein Myo2, the microtubule end-binding

220 Myo4p is a nonessential type V myosin required for the bud tip localization of A

221 COPI coatomer subunit in the targeting of a type V myosin to the late Golgi in yeast.

222 We show that Mlc1p, a light chain for Myo2p (type V myosin) and Iqg1p (IQGAP), is the essential light

223 and have delocalized actin patch and myo52p (type V myosin) distributions.

224 vement is specifically dependent on Myo2p, a type V myosin, and not on Myo4p, another type V myosin,

225 sites, bundling by cross-linkers, pulling by type V myosin, and severing by cofilin are simulated as

226 originally identified as a light chain for a type V myosin, Myo2p; however, a cytokinesis defect asso

227 , a type V myosin, and not on Myo4p, another type V myosin, or Myo3p and Myo5p, type I myosins.

228 ecruiting the She2p-mRNA complex to Myo4p, a type V myosin.

229 Finally, the vacuole-specific type-V myosin adapter Vac17p interacts with Atg18p, perh

230 Focalization requires Fus1 and type V myosins and happens asynchronously always in the

231 Type V myosins are essential for fusion and concentrate

232 py and live-cell imaging of Fus1, actin, and type V myosins revealed an aster of actin filaments whos

233 otation and this requires both actin and two type V myosins, Myo51 and Myo52.

234 Type V neurons provide information mainly about ITDs and

235 re than 1 year after colonoscopy, with polyp type vs no polyp after adjustment for year of colonoscop

236 Lamins, the type V nuclear intermediate filament proteins, are repor

237 y widespread answer to these problems is the type V (or autotransporter) secretion pathway.

238 the first biochemical characterization of a type V P-type ATPase, implicates Cod1p in ER function an

239 tition assay between the DeltatoxRS and wild-type V. parahaemolyticus strains marked with the beta-ga

240 The wild-type V pH-rate profile decreases below a pK of 5.2 and i

241 Type V phosphodiesterase (PDE V) metabolizes cyclic guan

242 LTD by a 30 min treatment of slices with the type V phosphodiesterase inhibitor zaprinast (20 microm)

243 he first characterization of an F. nucleatum Type Vd phospholipase class A1 autotransporter (strain A

244 essing of the most prevalent in vivo form of type V procollagen.

245 ette C, containing an IFN-antagonistic, wild-type V protein (rBC), (ii) an isogenic recombinant virus

246 bits minigenome replication as does the wild-type V protein.

247 Type V represents another different three-component syst

248 for common ancestral origins of type III and type V RTKs.

249 For the p-type and one of the n-type v-SAND-based OFETs, the performance (under vacuum a

250 Collagen type V(SC) blocked axonal outgrowth in the presence of o

251 hat in embryonic peripheral nerves, collagen type V(SC) plays a dual role in regulating cell migratio

252 ganglion neurons and Schwann cells, collagen type V(SC) promoted axon fasciculation and association o

253 om Schwann cell conditioned medium (collagen type V(SC)) promoted migration of Schwann cells but inhi

254 mbrane protein IcsA belongs to the family of type V secreted (autotransported) virulence factors.

255 The type V secreted autotransporter serine protease EspP and

256 leatum strains contain genomic expansions of Type V secreted effectors (autotransporters) that are cr

257 detect, track, and characterize the role of Type Vd secreted phospholipases in Gram-negative bacteri

258 Many proteins secreted by the type V secretion system (autotransporters) have been lin

259 are outer membrane proteins belonging to the type V secretion system family, and many have been shown

260 rters (ATs) are exoproteins belonging to the type V secretion system family, with many playing roles

261 and flagella-specific type III, type IV, and type V secretion systems as well as adhesins, invasins,

262 e bacteria exchange polymorphic toxins using type V secretion systems.

263 Whereas the role of Type Vd secretion in bacteria remains unidentified, we s

264 en two different strains of C. elegans (wild-type vs slcf-1 mutant).

265 ting for vesicle-associated membrane protein type v-SNARE proteins (or synaptobrevins) reveals charac

266 lture conditions, compared with that of wild-type V strains.

267 protein of Escherichia coli secreted by the Type V, subtype a, secretion system (T5aSS) and belongin

268 brains at ages of E13 and P5 (in particular type V), suggesting roles in early neural development an

269 Here we show that an antitoxin from a type V system (GhoS, an endoribonuclease specific for th

270 ependent growth inhibition system (CDI) is a Type V system, using a long beta-helical cell surface pr

271 The type V TGF-beta receptor (TbetaR-V) mediates IGF-indepen

272 The type V TGF-beta receptor (TbetaR-V)/IGFBP-3 receptor med

273 majority of the collagen mass, and collagen type V, the functions of which are poorly understood, is

274 For type V, the relative risk was 0.3 (95% CI, .01-3.1), cor

275 compound 2a is of comparable potency in wild type vs thymidine kinase deficient LM cells.

276 these five proteins inhibited binding of GBS type V to ME-180 cells by > or =85%.

277 in the shape of infiltration isotherms (from type-V to type-I), which denotes a sharp passage from ty

278 ions were equally severe in Fitzpatrick skin types V to VI and I to IV, with minimal erythemal doses

279 Tartrate-resistant acid phosphatase (type V) (TRAP) was used as the bait in a biopanning proc

280 vered via diverse secretory systems, such as Type V, Type VI, PVC and a novel PrsW-like intramembrane

281 potent and specific blocker of the vacuolar-type (V-type) ATPase, which eliminates the driving force

282 The membrane rotor ring from the vacuolar-type (V-type) sodium ion-pumping adenosine triphosphatas

283 dentified Cas14 family and distantly related type V-U3 Cas proteins found in bacteria.

284 cines are immunogenic in healthy adults, but type V vaccines have not previously been tested.

285 ge, and another group encodes an inactivated type V variant.

286 0.88 for type I/II, type III/IV and advanced type V/VI lesions, respectively (p < 0.03).

287 ups: the first group comprised of vulnerable type V/VI lesions; the second group, stable type I/II le

288 holinergic receptors, Galpha(s), and cardiac types V/VI adenylyl cyclase distribute between caveolae

289 suggest that Schwann cells bind to collagen type V via syndecan-3-dependent binding to a novel high

290 ) increases alternative mRNA splicing of the type V, voltage-gated cardiac Na+ channel alpha-subunit

291 e most common rtxA1 gene variant in clinical-type V. vulnificus encodes a toxin with reduced potency

292 collagen domain of pepsin-digested collagen type V was poorly adhesive for Schwann cells.

293 phas-insensitive mutants of adenylyl cyclase type V were used to test the hypothesis that heterologou

294 pes III and II, followed by either type I or type V, while types IV and VI are the least abundant.

295 The N-propeptide of collagen type V/XI and the NC2 domain of type IX collagen both co

296 All three B-clade type V/XI collagen chains revealed the same three sites

297 nomer is type II as in articular cartilage), type V/XI collagen consisted of a mix of five geneticall

298 Collagen type V/XI is a minor but essential component of collagen

299 ations were obtained when contributions from types V/XI and IX collagen were included in the simulati

300 hancement of NK cell activation through wild-type vs. Y238F mutant NKp44.